A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell therapy. Researchers will study whether these voice recordings and assessments are a practical (feasible) way to monitor for immune effector cell-associated neurotoxicity syndrome (ICANS). Feasibility will be measured by tracking how many participants join the study and complete the assessments.

NCT Number	NCT07249528
Lead Sponsor	Memorial Sloan Kettering Cancer Center
Conditions	Non-hodgkin Lymphoma, Multiple Myeloma
Enrollment	20 participants
Start Date	2026-04-17
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-06